**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 28859**

**Manuscript Type:****ORIGINAL ARTICLE**

***Retrospective Cohort Study***

**Risk stratification for malignant progression in Barrett’s esophagus: Gender, age, duration and year of surveillance**

Gatenby P *et al.* Risk stratification for malignant progression in Barrett’s esophagus

Piers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson

**Piers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson,** UK Barrett’s Oesophagus Registry, UCL, NW32QG London, United Kingdom

**Piers Gatenby,** Regional Oesophagogastric Unit, Royal Surrey County Hospital, Guildford, GU2 7XH Surrey, United Kingdom

**Piers Gatenby,** Department of Clinical and Experimental Medicine, University of Surrey, Guildford, GU2 7XH Surrey, United Kingdom

**Author** **contributions**: All authors contributed to this manuscript with writing, designing, and final approval.

**Supported by** The Barrett’s Oesophagus Campaign; The Wexham Gastrointestinal Trust; The Childwick Trust, The R. L. St J. Harmsworth Memorial Research Fund; and The David and Frederick Barclay Foundation

**Conflict-of-interest** **statement:** None declared, the authors confirm that we have no financial arrangements related to the research or manuscript preparation to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Piers Gatenby, MA MD FRCS,** Division of Surgery and Interventional Science, UCL, Royal Free Campus, Pond Street, NW32QG London, United Kingdom. [p.gatenby@ucl.ac.uk](mailto:p.gatenby@ucl.ac.uk)

**Telephone:** +44-20-76792000

**Received:** July 18, 2016

**Peer-review started:** July 20, 2016

**First decision:** September 20, 2016

**Revised:** October 17, 2016

**Accepted:** November 23, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To clarify risk based upon segment length, diagnostic histological findings, patient age and year of surveillance, duration of surveillance and gender.

***METHODS***

Patients registered with the UK Barrett’s Oesophagus Registry from 9 UK centers were included. The outcome measures were (1) development of all grades of dysplasia; (2) development of high-grade of dysplasia or adenocarcinoma; and (3) development of adenocarcinoma. Prevalent cases and subjects with < 1 year of follow-up were excluded. The covariates examined were segment length, previous biopsy findings, age at surveillance, duration of surveillance, year of surveillance and gender.

***RESULTS***

One thousand and one hundred thirty six patients were included (total 6474 patient-years). 54 patients developed adenocarcinoma (0.83% per annum), 70 developed high-grade dysplasia/adenocarcinoma (1.1% per annum) and 190 developed any grade of dysplasia (3.5% per annum). High grade dysplasia and adenocarcinoma increased with age and duration of surveillance. The risk of low-grade dysplasia development was not dependent on age at surveillance. Segment length and previous biopsy findings were also significant factors for development of dysplasia and adenocarcinoma.

***CONCLUSION***

The risk of development of low-grade dysplasia is independent of age at surveillance, but high-grade dysplasia and adenocarcinoma were more commonly found at older age. Segment length and previous biopsy findings are also markers of risk. This study did not demonstrate stabilisation of the metaplastic segment with prolonged surveillance.

**Key words:** Barrett‘s esophagus; Esophageal neoplasms;Public health;Epidemiology; Surveillance;Dysplasia

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Current surveillance guidelines for Barrett’s oesophagus base the enrolment into surveillance and surveillance interval on segment length, presence or absence of intestinal metaplasia and dysplasia. This study demonstrates the importance of age as an important risk factor for high-grade dysplasia and adenocarcinoma development and that stabilisation of the epithelium does not reliably occur at long-term follow-up.

Gatenby P, Bhattacharjee S, Wall C, Caygill C, Watson A. Risk stratification for malignant progression in Barrett’s esophagus: Gender, age, duration and year of surveillance. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

The incidence of adenocarcinoma in Barrett’s esophagus has been estimated to be around 0.5% per annum[1-3] and 0.32% in patients without dysplasia at index endoscopy[4]. This would suggest a lifetime risk of around 1:8 to 1:14 of developing adenocarcinoma and 1:5 to 1:6 of developing either high-grade dysplasia or adenocarcinoma[5]. A meta-analysis has shown a trend for a decrease in incidence of adenocarcinoma to be observed with time (which did not reach statistical significance, *P =* 0.117)[3] and in recent years large population-based cohort studies[6-8] have demonstrated lower adenocarcinoma incidence rates (0.22%, 0.43% and 0.12% per annum respectively). We have observed that the age at diagnosis of patients with Barrett’s esophagus is falling[9] and that the life expectancy of those diagnosed with Barrett’s esophagus is increasing[5]. The Danish pathology registry has demonstrated in their cohort that the adenocarcinoma incidence in Barrett’s increases with older age[8].

The currently accepted principal risk factors for dysplasia and cancer development in Barrett’s oeosphagus are presence/absence of intestinal metaplasia, dysplasia and segment length[10-12]. These are the factors on which guidance for surveillance intervals are determined.

These observations prompt examination of what the time trends in cancer incidence in Barrett’s esophagus are: Are the annual incidences of dysplasia and cancer changing in the population with Barrett’s esophagus undergoing surveillance? Does an individual’s risk change over time dependent on the patient’s age at the time of surveillance? Does the Barrett’s segment stabilize with prolonged follow-up such that patients might be reassured and discharged from further follow-up?

This study seeks to examine whether there is a demonstrable change in incidence of dysplasia and adenocarcinoma over time in patients undergoing surveillance of Barrett’s esophagus who are registered with the UK Barrett’s Oesophagus Registry and which are the most important demographic, histological and endoscopic features with regard to dysplasia and cancer risk.

**MATERIALS AND METHODS**

One thousand one hundred and thirty six patients who had been registered with the UK Barrett’s Oesophagus Registry from 9 centers who did not have prevalent adenocarcinoma (diagnosed at index endoscopy or within one year of the index endoscopy) and who had a minimum of one year of follow-up were included in the study cohort. The three outcome measures were (1) Development of any grade of dysplasia; (2) Development of high-grade dysplasia or adenocarcinoma; and (3) Development of adenocarcinoma. Follow-up time commenced at the diagnostic biopsy and was censored at the first biopsy reported as demonstrating the histological outcome or, when this was not attained, the final surveillance endoscopy and biopsy. The influence of 7 factors was then considered to provide further clarity as to an individual’s risk of development of dysplasia and cancer. These were: (1) date (year) at which surveillance biopsies were undertaken; (2) age of the patient at which surveillance endoscopy and biopsy were undertaken; (3) length of time during which the patient had been undergoing surveillance; (4) patient gender; (5) segment length; (6) histological findings at the most recent (previous) endoscopy; and (7) histological findings at first and second endoscopies (in keeping with national guidelines on enrolment into surveillance programmes[10-12]).

Classification of histological results were: columnar-lined oesophagus without intestinal metaplasia, columnar-lined oesophagus with intestinal metaplasia, indefinite changes for dysplasia, low-grade dysplasia, high-grade dysplasia and adenocarcinoma.

The associations of dysplasia/adenocarcinoma risk with age at surveillance, year of surveillance and duration of surveillance were examined.

The associations between these factors and risk of development of dysplasia or cancer were examined using binary logistic regression. The model was modified to exclude factors which did not reach statistical significance with removal of factors which showed no association with dysplasia or cancer risk. Due to the co-linearity of age, surveillance duration and year of surveillance, only the most closely-associated of these three variables was included in the final analyses.

Segment length data were available for 92.4% of cases and the analyses were repeated with the exclusion of segment length. Segment length was examined as a continuous variable and when separated into three similarly sized and clinically relevant groups: short segment (< 3 cm), 3-5 cm and > 5 cm.

***Ethical permission***

Approval for studies of this kind conducted by UKBOR was given by the London Multi-Centre Research Ethics Committee on 14th March 2002 number MREC/02/2/5.

***Statistical analysis***

Incidence calculations were undertaken using a patient-years at risk method and expressed as an annual percentage (cases per one hundred patient-years follow-up) and 95% confidence intervals were evaluated using an exact Poisson distribution. Logistic regression to ascertain the magnitude of the effect of the covariates was undertaken. *P* values < 0.05 were taken to be statistically significant.

**RESULTS**

The 1136 patients who fulfilled the criteria for inclusion in the study cohort comprised 783 males and 353 females diagnosed between 1974 and 2009. The mean age at diagnosis was 59.8 years, mean follow-up was 5.70 years and total follow-up was 6474 patient-years. The mean age at surveillance was 62.3 years, with a small trend for this to rise in males (60 in the 1990s, 61 in 2000-2004 and 62 from 2005 onwards), but no change in females (mean age at surveillance 65). During the follow-up period 54 patients developed adenocarcinoma, 70 developed either high-grade dysplasia or adenocarcinoma and 190 developed changes of any grade of dysplasia or cancer. The overall annual incidence of development of adenocarcinoma was 0.83% per annum, of high-grade dysplasia or adenocarcinoma, 1.1% per annum and of all grades of dysplasia and adenocarcinoma, 3.5% per annum.

***Time trends for population during the cohort***

During the first 15 years of the cohort from 1974-1989 only a small number of patients (76) were diagnosed and underwent surveillance, hence these patients have been grouped together; thereafter, dysplasia and adenocarcinoma incidence were examined over consecutive 5 year periods (see Table 1).

***Risk with year of surveillance***

These data demonstrate that there was no clear trend for the incidence of either dysplasia or adenocarcinoma to fall appreciably during the study period (as examined by year of surveillance). The mean age at surveillance remained constant throughout the cohort; however there was an increased proportion of males in the latter portion of the cohort. When males and females were examined separately, there was no demonstrable change in the incidence of either adenocarcinoma or high-grade dysplasia for females with year of surveillance and a trend for a slight increase in adenocarcinoma incidence with later year of surveillance for males. The adenocarcinoma and high-grade dysplasia incidences were similar in males and females, but slightly lower in females. These results are depicted graphically in Figures 1 and 2.

***Risk with age at surveillance***

Table 2 and Figures 3 and 4 show the effect of age at surveillance on the detection of dysplasia and adenocarcinoma. This demonstrates a trend for an increasing risk of dysplasia detection as age at surveillance increases. When males and females were analysed separately, there was a trend for higher rates of dysplasia and adenocarcinoma incidence in males compared to females for specific decade of age at surveillance, but overall similar rates due to females being older than males at surveillance (40% of surveillance of females within the cohort occurring at age > 70, compared to 25% for males).

***Risk with duration of surveillance***

The results of the analysis which examined whether the risk of development of dysplasia and adenocarcinoma remains constant during the course of an individual patient’s surveillance are shown in Table 3 and Figures 5 and 6. These demonstrate that there is a trend for increasing risk of development of high-grade dysplasia and adenocarcinoma with increasing duration of surveillance, but not of development of low-grade dysplasia. When males and females were analyzed separately, there did not appear to be a significant effect of gender on the results.

***Logistic regression analyses***

Initially all 7 variables were included in the logistic regression analyses. Gender was excluded as there was no association with the outcome measures and year at surveillance and duration of surveillance were also excluded as the association between the outcome variables was strongest with age at surveillance. For the outcome variables of high-grade dysplasia and adenocarcinoma: the final model showed that the statistically significantly associated factors were age at surveillance, segment length and previous histological biopsy grading. For the development of all grades of dysplasia and cancer: segment length and the findings at the first two biopsies reached statistical significance. These results are shown in Table 4.

**DISCUSSION**

These results demonstrate that there was no clear evidence of any change in overall adenocarcinoma or dysplasia incidence throughout the cohort period nor for the risk of development of all grades of dysplasia to change with increasing duration of follow-up. The risk of development of high-grade dysplasia and adenocarcinoma tended to increase with increased duration of surveillance, but more strikingly: there was a relationship between older age at surveillance and higher rate of detection of high-grade dysplasia and adenocarcinoma.

These observations demonstrate that the metaplastic segment does not remain stable with prolonged follow-up: the rate of development of all grades of dysplasia remained around 3.5% per annum and there was a trend for increased risk of high-grade dysplasia and adenocarcinoma development at increased duration of follow-up in common with the Dutch cohort[7].

From the logistic regression, the most significant time-dependent factor is age at surveillance (with increasing risks of development of high-grade dysplasia or cancer at older age).

Subsequently, this analysis has not demonstrated that after a prolonged period of stability there are patients who might be safely discharged from surveillance.

This observation would suggest that younger patients could undergo less intensive surveillance than older patients (with respect to development of high-grade dysplasia or adenocarcinoma), however younger patients potentially have longer periods of exposure to the risk of developing these changes and conceivably an increased lifetime risk[13]. These observations parallel those on esophageal cancer incidence in the UK population[14]. We have also observed that the average age at diagnosis of Barrett’s esophagus is falling[9], which, whilst this may subsequently result in a reduction in the annual incidence of adenocarcinoma for the surveillance cohort overall, it will not result in any risk reduction for an individual patient[5].

Overall, females and males had similar risk of development of dysplasia and cancer in this cohort, however it is likely that this is in part due to the larger proportion of females undergoing surveillance at older age compared to males and that the risk for females when age-matched is lower than in males. Similar results were shown in the Dutch national cohort[7]. With higher life expectancy for females, this is an important consideration and this study does not provide data to support the suggestion that females might be safely discharged from surveillance. The Dutch cohort also confirmed the high cancer risk in older females[7]. Different proportions of older patients undergoing surveillance may explain some of the variability seen in the incidence of high-grade dysplasia and adenocarcinoma in published studies.

The risk for any individual patient will depend on a number of factors, some of which are modifiable and others which cannot be modified[15]. Caucasian ethnic origin[16], male gender[6,8,17], older age at diagnosis[8,18,19], longer Barrett’s segment length[3,17,20,21] and the presence of dysplasia at diagnosis[6,8,20,22] have each been reported to be markers of higher malignant risk determined at the time of diagnosis. Longer duration of surveillance was also associated with increased cancer risk, but without separately examining the age at which surveillance was undertaken[20]. The role of intestinal metaplasia remains controversial[1,6,23-26]. Obesity[17,27,28], optimal reflux control[29-35], diet (poor intake of fruit, vegetables and anti-oxidants)[17,36,37], smoking[17,28,38,39] and medication use (particularly aspirin[40], non-steroidal anti-inflammatory drugs[41-43] and statins[40,44-46]) will influence an individual’s risk at the time of diagnosis and subsequently. These modifiable factors should be addressed by public health programs and medical care. Additionally, absence of Helicobacter Pylori infection has been associated with higher prevalence of Barrett’s esophagus and dysplasia than in subjects who have had Helicobacter Pylori infection[47]. It seems likely that much of the fate of the metaplastic segment is determined prior to the time of diagnosis. Once diagnosed, reflux control, smoking, medication use, diet and control of obesity may be managed, but unless the potentially malignant tissue is either completely resected or ablated, cancer risk in this tissue remains.

Encouraging data on the role of endoscopic ablation of the metaplastic segment have now been published, however long-term follow-up with respect to cancer development is awaited[48-50].

Unfortunately, the incidence of Barrett’s esophagus[51-55] and esophageal adenocarcinoma[56-58] are increasing and without improved strategies to reduce the risk of cancer development within the population at risk and the size of this population, the number of cases of esophageal adenocarcinoma is likely to continue to rise[13].

The results of this study demonstrate that age at surveillance is an important factor for high-grade dysplasia and adenocarcinoma development and should be incorporated (with segment length and previous biopsy findings) into risk assessment in Barrett’s oesophagus surveillance.

**ACKNOWLEDGEMENTS**

We would like to thank the registrants for enabling the work to take place (see Supplementary Table).

**COMMENTS**

***Background***

The age at diagnosis of patients with Barrett’s esophagus is fallingand that the life expectancy of those diagnosed with Barrett’s esophagus is increasing. The Danish pathology registry has demonstrated in their cohort that the adenocarcinoma incidence in Barrett’s increases with older age**.**

***Research frontiers***

The currently accepted principal risk factors for dysplasia and cancer development in Barrett’s oeosphagus are presence/absence of intestinal metaplasia, dysplasia and segment length. These are the factors on which guidance for surveillance intervals are determined.

***Innovations and breakthroughs***

Seek to clarify risk based upon segment length, diagnostic histological findings, patient age and year of surveillance, duration of surveillance and gender.

***Applications***

This study demonstrates the importance of age as an important risk factor for high-grade dysplasia and adenocarcinoma development and that stabilisation of the epithelium does not reliably occur at long-term follow-up.

***Peer-review***

Interesting and practical paper, the relation between Barrett's esophagus and adenocarcinoma was very important.

**REFERENCES**

1 **Yousef F**, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. *Am J Epidemiol* 2008; **168**: 237-249 [PMID: 18550563 DOI: 10.1093/aje/kwn121]

2 **Sikkema M**, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2010; **8**: 235-44; quiz e32 [PMID: 19850156 DOI: 10.1016/j.cgh.2009.10.010]

3 **Thomas T**, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: Cancer risk in Barrett's oesophagus. *Aliment Pharmacol Ther* 2007; **26**: 1465-1477 [PMID: 17900269 DOI: 10.1111/j.1365-2036.2007.03528.x]

4 **Desai TK**, Krishnan K, Samala N, Singh J, Cluley J, Perla S, Howden CW. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. *Gut* 2012; **61**: 970-976 [PMID: 21997553 DOI: 10.1136/gutjnl-2011-300730]

5 **Gatenby P**, Caygill C, Wall C, Bhatacharjee S, Ramus J, Watson A, Winslet M. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus. *World J Gastroenterol* 2014; **20**: 9611-9617 [PMID: 25071359]

6 **Bhat S**, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. *J Natl Cancer Inst* 2011; **103**: 1049-1057 [PMID: 21680910 DOI: 10.1093/jnci/djr203]

7 **de Jonge PJ**, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. *Gut* 2010; **59**: 1030-1036 [PMID: 20639249 DOI: 10.1136/gut.2009.176701]

8 **Hvid-Jensen F**, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med* 2011; **365**: 1375-1383 [PMID: 21995385 DOI: 10.1056/NEJMoa1103042]

9 **Wall CM**, Charlett A, Caygill CP, Gatenby PA, Ramus JR, Winslet MC, Watson A. Are newly diagnosed columnar-lined oesophagus patients getting younger? *Eur J Gastroenterol Hepatol* 2009; **21**: 1127-1131 [PMID: 19295439 DOI: 10.1097/MEG.0b013e328329c414]

10 **Fitzgerald RC**, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O'Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, Moayyedi P, Lyratzopoulos G, de Caestecker J. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut* 2014; **63**: 7-42 [PMID: 24165758 DOI: 10.1136/gutjnl-2013-305372]

11 **Spechler SJ**, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology* 2011; **140**: 1084-1091 [PMID: 21376940 DOI: 10.1053/j.gastro.2011.01.031]

12 **Wang KK**, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. *Am J Gastroenterol* 2008; **103**: 788-797 [PMID: 18341497 DOI: 10.1111/j.1572-0241.2008.01835.x]

13 **Gatenby PA**, Hainsworth A, Caygill C, Watson A, Winslet M. Projections for oesophageal cancer incidence in England to 2033. *Eur J Cancer Prev* 2011; **20**: 283-286 [PMID: 21422931 DOI: 10.1097/CEJ.0b013e32834572d2]

14 Office for National Statistics: Cancer Registrations in England, 2010. In: Office for National Statistics. Newport, Wales, UK: UK Statistics Authority, 2012

15 **Gatenby P**, Soon Y. Barrett's oesophagus: Evidence from the current meta-analyses. *World J Gastrointest Pathophysiol* 2014; **5**: 178-187 [PMID: 25133020]

16 **Khoury JE**, Chisholm S, Jamal MM, Palacio C, Pudhota S, Vega KJ. African Americans with Barrett's esophagus are less likely to have dysplasia at biopsy. *Dig Dis Sci* 2012; **57**: 419-423 [PMID: 21909989 DOI: 10.1007/s10620-011-1900-y]

17 **Pohl H**, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rösch T, Baumgart DC. Risk factors in the development of esophageal adenocarcinoma. *Am J Gastroenterol* 2013; **108**: 200-207 [PMID: 23247577 DOI: 10.1038/ajg.2012.387]

18 **den Hoed CM**, van Blankenstein M, Dees J, Kuipers EJ. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. *Br J Cancer* 2011; **105**: 200-205 [PMID: 21673678 DOI: 10.1038/bjc.2011.214]

19 **Gatenby PA**, Caygill CP, Ramus JR, Charlett A, Watson A. Barrett's columnar-lined oesophagus: demographic and lifestyle associations and adenocarcinoma risk. *Dig Dis Sci* 2008; **53**: 1175-1185 [PMID: 17939050 DOI: 10.1007/s10620-007-0023-y]

20 **Sikkema M**, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, van Vuuren AJ, Bode WA, van der Valk H, Ouwendijk RJ, Giard R, Lesterhuis W, Heinhuis R, Klinkenberg EC, Meijer GA, ter Borg F, Arends JW, Kolkman JJ, van Baarlen J, de Vries RA, Mulder AH, van Tilburg AJ, Offerhaus GJ, ten Kate FJ, Kusters JG, Kuipers EJ, Siersema PD. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. *Am J Gastroenterol* 2011; **106**: 1231-1238 [PMID: 21577245 DOI: 10.1038/ajg.2011.153]

21 **Gatenby PA**, Caygill CP, Ramus JR, Charlett A, Fitzgerald RC, Watson A. Short segment columnar-lined oesophagus: an underestimated cancer risk? A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. *Eur J Gastroenterol Hepatol* 2007; **19**: 969-975 [PMID: 18049166 DOI: 10.1097/MEG.0b013e3282c3aa14]

22 **Gatenby P**, Ramus J, Caygill C, Shepherd N, Winslet M, Watson A. Routinely diagnosed low-grade dysplasia in Barrett's oesophagus: a population-based study of natural history. *Histopathology* 2009; **54**: 814-819 [PMID: 19635100 DOI: 10.1111/j.1365-2559.2009.03316.x]

23 **Kelty C**, Gough M, Van Wyck Q, Stephenson T, Ackroyd R: Barrett's oesophagus: Intestinal metaplasia is not essential for cancer risk. *Scand J Gastroenterol* 2007; **21**: 1-4 [DOI: 10.1080/00365520701420735]

24 **Gatenby PA**, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. *Scand J Gastroenterol* 2008; **43**: 524-530 [PMID: 18415743 DOI: 10.1080/00365520701879831]

25 **Dias Pereira A**, Chaves P. Columnar-lined oesophagus without intestinal metaplasia: results from a cohort with a mean follow-up of 7 years. *Aliment Pharmacol Ther* 2012; **36**: 282-289 [PMID: 22670705 DOI: 10.1111/j.1365-2036.2012.05170.x]

26 **Westerhoff M**, Hovan L, Lee C, Hart J. Effects of dropping the requirement for goblet cells from the diagnosis of Barrett's esophagus. *Clin Gastroenterol Hepatol* 2012; **10**: 1232-1236 [PMID: 22642957 DOI: 10.1016/j.cgh.2012.05.013]

27 **Duggan C**, Onstad L, Hardikar S, Blount PL, Reid BJ, Vaughan TL: Association Between Markers of Obesity and Progression From Barrett's Esophagus to Esophageal Adenocarcinoma. *Clin Gastroenterol Hepatol* 2013; **11**:934-943 [PMID: 23466711 DOI: 10.1016/j.cgh.2013.02.017]

28 **Hardikar S**, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL. The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. *PLoS One* 2013; **8**: e52192 [PMID: 23300966 DOI: 10.1371/journal.pone.0052192]

29 **Braghetto I**, Korn O, Valladares H, Debandi A, Díaz JC, Brunet L. Laparoscopic surgical treatment for patients with short- and long-segment Barrett's esophagus: which technique in which patient? *Int Surg* 2011; **96**: 95-103 [PMID: 22026298 DOI: 10.9738/CC29.1]

30 **Zaninotto G**, Parente P, Salvador R, Farinati F, Tieppo C, Passuello N, Zanatta L, Fassan M, Cavallin F, Costantini M, Mescoli C, Battaglia G, Ruol A, Ancona E, Rugge M. Long-term follow-up of Barrett's epithelium: medical versus antireflux surgical therapy. *J Gastrointest Surg* 2012; **16**: 7-14; discussion 14-5 [PMID: 22086718 DOI: 10.1007/s11605-011-1739-8]

31 **Li YM**, Li L, Yu CH, Liu YS, Xu CF. A systematic review and meta-analysis of the treatment for Barrett's esophagus. *Dig Dis Sci* 2008; **53**: 2837-2846 [PMID: 18427992 DOI: 10.1007/s10620-008-0257-3]

32 **Corey KE**, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. *Am J Gastroenterol* 2003; **98**: 2390-2394 [PMID: 14638338 DOI: 10.1111/j.1572-0241.2003.08702.x]

33 **Rees JR**, Lao-Sirieix P, Wong A, Fitzgerald RC: Treatment for Barrett's oesophagus. *Cochrane Database Syst Rev* 2010; CD004060 [DOI: 10.1002/14651858.cd004060.pub2]

34 **Gatenby PA**, Ramus JR, Caygill CP, Charlett A, Winslet MC, Watson A. Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. *Dis Esophagus* 2009; **22**: 133-142 [PMID: 19018855 DOI: 10.1111/j.1442-2050.2008.00886.x]

35 **Kastelein F**, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, Bruno MJ. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. *Clin Gastroenterol Hepatol* 2013; **11**: 382-388 [PMID: 23200977 DOI: 10.1016/j.cgh.2012.11.014]

36 **Lukić M**, Segec A, Segec I, Pinotić L, Pinotić K, Atalić B, Solić K, Vcev A. The impact of the vitamins A, C and E in the prevention of gastroesophageal reflux disease, Barrett's oesophagus and oesophageal adenocarcinoma. *Coll Antropol* 2012; **36**: 867-872 [PMID: 23213946]

37 **Ibiebele TI**, Hughes MC, Nagle CM, Bain CJ, Whiteman DC, Webb PM. Dietary antioxidants and risk of Barrett's esophagus and adenocarcinoma of the esophagus in an Australian population. *Int J Cancer* 2013; **133**: 214-224 [PMID: 23292980 DOI: 10.1002/ijc.28016]

38 **Coleman HG**, Bhat S, Johnston BT, McManus D, Gavin AT, Murray LJ. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. *Gastroenterology* 2012; **142**: 233-240 [PMID: 22062359 DOI: 10.1053/j.gastro.2011.10.034]

39 **Ramus JR**, Gatenby PA, Caygill CP, Watson A, Winslet MC. The relationship between smoking and severe dysplastic disease in patients with Barrett's columnar-lined oesophagus. *Eur J Cancer Prev* 2012; **21**: 507-510 [PMID: 22433630 DOI: 10.1097/CEJ.0b013e328350b06f]

40 **Beales IL**, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. *Eur J Gastroenterol Hepatol* 2012; **24**: 917-923 [PMID: 22569083 DOI: 10.1097/MEG.0b013e3283543f01]

41 **Wang F**, Lv ZS, Fu YK. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. *Dis Esophagus* 2011; **24**: 318-324 [PMID: 21166737 DOI: 10.1111/j.1442-2050.2010.01153.x]

42 **Liao LM**, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, Abnet CC, Risch HA, Giffen C, Freedman ND, Chow WH, Sadeghi S, Pandeya N, Whiteman DC, Murray LJ, Bernstein L, Gammon MD, Wu AH. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. *Gastroenterology* 2012; **142**: 442-452.e5; quiz e22-3 [PMID: 22108196 DOI: 10.1053/j.gastro.2011.11.019]

43 **Thrift AP**, Pandeya N, Smith KJ, Green AC, Webb PM, Whiteman DC. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. *Aliment Pharmacol Ther* 2011; **34**: 1235-1244 [PMID: 21967506 DOI: 10.1111/j.1365-2036.2011.04855.x]

44 **Kantor ED**, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. *Cancer Epidemiol Biomarkers Prev* 2012; **21**: 456-461 [PMID: 22241250 DOI: 10.1158/1055-9965.EPI-11-1014]

45 **Alexandre L**, Clark AB, Cheong E, Lewis MP, Hart AR. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. *Aliment Pharmacol Ther* 2012; **36**: 301-311 [PMID: 22716127 DOI: 10.1111/j.1365-2036.2012.05194.x]

46 **Singh S**, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 620-629 [PMID: 23357487 DOI: 10.1016/j.cgh.2012.12.036]

47 **Thrift AP**, Pandeya N, Smith KJ, Green AC, Hayward NK, Webb PM, Whiteman DC. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. *Int J Cancer* 2012; **130**: 2407-2416 [PMID: 21681741 DOI: 10.1002/ijc.26242]

48 **Phoa KN**, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, Fullarton G, Di Pietro M, Ravi N, Visser M, Offerhaus GJ, Seldenrijk CA, Meijer SL, ten Kate FJ, Tijssen JG, Bergman JJ. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. *JAMA* 2014; **311**: 1209-1217 [PMID: 24668102 DOI: 10.1001/jama.2014.2511]

49 **Shaheen NJ**, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ. Radiofrequency ablation in Barrett's esophagus with dysplasia. *N Engl J Med* 2009; **360**: 2277-2288 [PMID: 19474425 DOI: 10.1056/NEJMoa0808145]

50 **Fleischer DE**, Overholt BF, Sharma VK, Reymunde A, Kimmey MB, Chuttani R, Chang KJ, Muthasamy R, Lightdale CJ, Santiago N, Pleskow DK, Dean PJ, Wang KK. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. *Endoscopy* 2010; **42**: 781-789 [PMID: 20857372 DOI: 10.1055/s-0030-1255779]

51 **Corley DA**, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. *Gut* 2009; **58**: 182-188 [PMID: 18978173 DOI: 10.1136/gut.2008.163360]

52 **Caygill CP**, Reed PI, Johnston BJ, Hill MJ, Ali MH, Levi S. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. *Eur J Gastroenterol Hepatol* 1999; **11**: 1355-1358 [PMID: 10654794 DOI: 10.1097/00042737-199912000-00003]

53 **Coleman HG**, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett's oesophagus: a population-based study. *Eur J Epidemiol* 2011; **26**: 739-745 [PMID: 21671079 DOI: 10.1007/s10654-011-9596-z]

54 **van Soest EM**, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. *Gut* 2005; **54**: 1062-1066 [PMID: 15857935 DOI: 10.1136/gut.2004.063685]

55 **Alexandropoulou K**, van Vlymen J, Reid F, Poullis A, Kang JY. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study. *Eur J Gastroenterol Hepatol* 2013; **25**: 15-21 [PMID: 23022985 DOI: 10.1097/MEG.0b013e3283595086]

56 **Lepage C**, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. *Am J Gastroenterol* 2008; **103**: 2694-2699 [PMID: 18853967 DOI: 10.1111/j.1572-0241.2008.02191.x]

57 **Pohl H**, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. *J Natl Cancer Inst* 2005; **97**: 142-146 [PMID: 15657344 DOI: 10.1093/jnci/dji181]

58 **Dikken JL**, Lemmens VE, Wouters MW, Wijnhoven BP, Siersema PD, Nieuwenhuijzen GA, van Sandick JW, Cats A, Verheij M, Coebergh JW, van de Velde CJ. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. *Eur J Cancer* 2012; **48**: 1624-1632 [PMID: 22317953 DOI: 10.1016/j.ejca.2012.01.009]

**P-Reviewer:** Ono T, Stasek M **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United Kingdom

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**C:\Users\Piers\Documents\Barrett's\Papers, Abstracts & Presentations\BSG 2011\Paper\Clarity paper\WJG submission\Figure 1.tif**

**Figure 1 Annual incidence of adenocarcinoma and dysplasia dependent on calendar year of surveillance.**

**C:\Users\Piers\Documents\Barrett's\Papers, Abstracts & Presentations\BSG 2011\Paper\Clarity paper\WJG submission\Figure 2.tif**

**Figure 2 Annual incidence of adenocarcinoma and dysplasia dependent on calendar year of surveillance and gender.**

**C:\Users\Piers\Documents\Barrett's\Papers, Abstracts & Presentations\BSG 2011\Paper\Clarity paper\WJG submission\Figure 3.tif**

**Figure 3 Annual incidence of adenocarcinoma and dysplasia dependent on age at surveillance.**

C:\Users\Piers\Documents\Barrett's\Papers, Abstracts & Presentations\BSG 2011\Paper\Clarity paper\WJG submission\Figure 4.tif

**Figure 4 Annual incidence of adenocarcinoma and dysplasia dependent on age at surveillance and gender.**

**C:\Users\Piers\Documents\Barrett's\Papers, Abstracts & Presentations\BSG 2011\Paper\Clarity paper\WJG submission\Figure 5.tif**

**Figure 5 Annual incidence of adenocarcinoma and dysplasia dependent on duration of surveillance.**

**C:\Users\Piers\Documents\Barrett's\Papers, Abstracts & Presentations\BSG 2011\Paper\Clarity paper\WJG submission\Figure 5.tif**

**Figure 6 Annual incidence of adenocarcinoma and dysplasia dependent on duration of surveillance and gender.**

**Table 1 Annual incidence of adenocarcinoma and dysplasia dependent on year of surveillance**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Calendar years** | **Total patient-years follow-up** | **Adenocarcinoma** | | **High-grade dysplasia and adenocarcinoma** | | **All grades of dysplasia and adenocarcinoma** | |
| Number of cases | Annual incidence | Number of cases | Annual incidence | Number of cases | Annual incidence |
| 1974-1989 | 237 | 0 | 0.00% | 0 | 0.00% | 1 | 0.46% |
| 1990-1994 | 753 | 1 | 0.13% | 1 | 0.13% | 9 | 1.33% |
| 1995-1999 | 1950 | 19 | 0.97% | 21 | 1.09% | 76 | 4.70% |
| 2000-2004 | 2058 | 15 | 0.73% | 23 | 1.12% | 60 | 3.63% |
| 2005- | 1477 | 19 | 1.29% | 25 | 1.17% | 44 | 3.66% |
| Total | 6474 | 54 | 0.83% | 70 | 1.09% | 190 | 3.54% |

**Table 2 Annual incidence of adenocarcinoma and dysplasia dependent on age at surveillance**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Age at surveillance** | **Total patient-years follow-up** | **Adenocarcinoma** | | **High-grade dysplasia and adenocarcinoma** | | **All grades of dysplasia and adenocarcinoma** | |
| Number of cases | Annual incidence | Number of cases | Annual incidence | Number of cases | Annual incidence |
| <40 | 236 | 0 | 0.00% | 1 | 0.42% | 4 | 1.89% |
| 40-49 | 740 | 0 | 0.00% | 2 | 0.27% | 15 | 2.30% |
| 50-59 | 1602 | 6 | 0.37% | 9 | 0.56% | 39 | 2.82% |
| 60-69 | 2154 | 15 | 0.70% | 20 | 0.94% | 63 | 3.66% |
| 70-79 | 1464 | 20 | 1.37% | 26 | 1.81% | 52 | 4.49% |
| 80+ | 278 | 13 | 4.67% | 12 | 4.34% | 17 | 7.18% |
| Total | 6474 | 54 | 0.83% | 70 | 1.09% | 190 | 3.54% |

**Table 3 Annual incidence of adenocarcinoma and dysplasia dependent on duration of surveillance**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Duration of surveillance (yr)** | **Total patient-years follow-up** | **Adenocarcinoma** | | **High-grade dysplasia and adenocarcinoma** | | **All grades of dysplasia and adenocarcinoma** | |
| Number of cases | Annual incidence | Number of cases | Annual incidence | Number of cases | Annual incidence |
| 1-2 | 1848 | 14 | 0.76% | 19 | 1.04% | 72 | 4.47% |
| 3-4 | 1235 | 9 | 0.73% | 11 | 0.90% | 41 | 4.02% |
| 5-9 | 1587 | 20 | 1.26% | 27 | 1.72% | 54 | 4.47% |
| 10+ | 668 | 11 | 1.65% | 13 | 1.96% | 23 | 4.52% |

**Table 4 Logistic regression results**

|  |  |  |  |
| --- | --- | --- | --- |
| **Factor** | **Development of all grades of dysplasia and cancer** | **Development of high-grade dysplasia or cancer** | **Development of cancer** |
| Age | *P =* 0.187 | *P =* 0.40 | *P =* 0.034 |
| Segment length | *P =* 0.043 | *P =* 0.121 | *P =* 0.129 |
| Most recent biopsy results |  | *P =* 0.058 | *P =* 0.047 |
| First two biopsy results | *P* < 0.001 |  |  |